Compare IDEXX Laboratories, Inc. (IDXX) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.8× Global X NASDAQ 100 Covered Call ETF's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| IDXX | QYLD | |
|---|---|---|
Market Cap | $40.43B | $8.49B |
Volume | 692,164 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $18.68 |
52-Week Low | $504.70 | $16.70 |
Typical Hold Time | 46 Days | 51 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
QYLD trades at $18.685 with minimal daily movement (+0.03%), showing technical bullish signals from moving averages but bearish oscillator readings including overbought RSI levels. The ETF maintains consistent monthly dividend distributions of $0.18 per share, though recent news highlights concerns about declining option premiums and long-term capital erosion despite the attractive yield.
The outlook remains cautious as covered call strategies limit upside participation during market rallies. While providing reliable income, QYLD faces structural headwinds including capped growth potential and potential tax reclassification of distributions. Investors should weigh the trade-off between high current yield and long-term total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
